Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 8/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081904 | 1.00 | SNCA (0.41) | SNCALPLLIPGPDGFRBKDR | |
| SCHEMBL24367505 | 0.84 | SNCA (0.36) | SNCALPLLIPGPDGFRBKDR | |
| SCHEMBL24365115 | 0.83 | SNCA (0.39) | SNCALPLLIPGPDGFRBKDR | |
| SCHEMBL489516 | 0.80 | HSD17B10 (0.49) | SNCALPLLIPGIRAK4 | |
| SCHEMBL18228061 | 0.79 | SNCA (0.43) | SNCALPLLIPGPDGFRBKDR | |
| SCHEMBL18230156 | 0.77 | SNCA (0.42) | SNCALPLLIPGPDGFRBKDR | |
| SCHEMBL18239747 | 0.77 | HTT (0.42) | SNCALPLLIPGPDGFRBKDR | |
| SCHEMBL29981144 | 0.76 | LOXL2 (0.51) | SNCALPLLIPGPDGFRBKDR | |
| SCHEMBL593486 | 0.75 | SNCA (0.57) | SNCALPLLIPG | |
| SCHEMBL29980753 | 0.75 | SNCA (0.40) | SNCALPLLIPGPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SNCA 1297/4885LPL 2221/4885LIPG 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.